<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02831543</url>
  </required_header>
  <id_info>
    <org_study_id>ID-REMO-301</org_study_id>
    <nct_id>NCT02831543</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Assess the Efficacy and Safety of Combination Therapy of Motireb 5/100 mg in Functional Dyspepsia Patients.</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>IlDong Pharmaceutical Co Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IlDong Pharmaceutical Co Ltd</source>
  <brief_summary>
    <textblock>
      A phase â…¢, multi-center, randomized, double-blinded, placebo and active comparator clinical
      trial to assess the efficacy and safety of combination therapy of Motireb 5/100 mg in
      functional dyspepsia patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The responder ratio of GOS(Global Overall Symptom)</measure>
    <time_frame>at the 4th week</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">354</enrollment>
  <condition>Functional Dyspepsia</condition>
  <arm_group>
    <arm_group_label>Motireb 5/100 mg t.i.d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Motireb 5/100 mg t.i.d + Placebo of Mosapride citrate t.i.d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mosapride citrate t.i.d</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo of Motireb 5/100 mg t.i.d + Mosapride citrate t.i.d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo t.i.d</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo of Motireb 5/100 mg t.i.d + Placebo of Mosapride citrate t.i.d</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Motireb 5/100 mg</intervention_name>
    <arm_group_label>Motireb 5/100 mg t.i.d</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mosapride citrate</intervention_name>
    <arm_group_label>Mosapride citrate t.i.d</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo t.i.d</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female aged 19 years or older

          2. Patient with functional dyspepsia met the ROME III criteria or symptom assessment form

        Exclusion Criteria:

          1. Patient with peptic ulcer or gastroesophageal reflux disease

          2. Patients with previous gastrointestinal surgery

          3. Patients with history of gastrointestinal bleeding, mechanical obstruction,
             perforation

          4. Patients with history of gastrointestinal cancer

          5. Patients with pancreatic disease (pancreatitis, pancreatic cancer, etc), biliary
             disease, inflammatory bowel disease, acute gastritis.

          6. Patients with Zollinger-Ellison syndrome

          7. Patients with irritable bowel syndrome

          8. Pregnant or lactating women

          9. Patients with hepatic abnormality

         10. Patients with renal dysfunction or chronic kidney disease

         11. Patients who are judged by the investigators to be unsuitable to participate in the
             clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nayoung Kim, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Min-Hee Kwon</last_name>
    <phone>82-2-526-3379</phone>
    <email>minhee@ildong.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yoan Park, Master</last_name>
    <phone>82-2-526-3524</phone>
    <email>yapark@ildong.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seong Nam</city>
        <state>Kyung-gi</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nayoung Kim, PhD, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nayoung Kim, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2016</study_first_submitted>
  <study_first_submitted_qc>July 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2016</study_first_posted>
  <last_update_submitted>July 11, 2016</last_update_submitted>
  <last_update_submitted_qc>July 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspepsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Mosapride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

